课题基金 / 基金详情

BIOLOGICAL MODIFICATION OF HUMAN GLIOMA CELLS IN VITRO

BIOLOGICAL MODIFICATION OF HUMAN GLIOMA CELLS IN VITRO
人胶质瘤细胞的体外生物学修饰
批准号:
3945278
负责人:
G CONSTANTOPOULOS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

G CONSTANTOPOULOS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Shedding of various products from the cell surface of cancer cells may have an important role in loss of adhesion, metastasis, generation of immune-blocking factors and other pathophysiologic aspects of cancer (Black PH, NEJM. 303:1315, 1980). Human glioma cells in tissue culture produce and shed in the media much greater amounts of glycosaminoglycans (GAGs) than normal glial cells (Glimelius et al Biochem J. 172:443, 1978). Glycosaminoglycans are polyanionic compounds, usually bound covalently to a protein core. They are a prominent component of the cell surface and are implicated in cell-cell interaction. There is also evidence for existence of hyaluronidase-sensitive protective coats on some neoplastic cell lines including gliomas, and it has been suggested that the protective GAG coat may impede the immune response and the efficacy of chemotherapy. Our objective was to modify or prevent the synthesis and shedding of GAGs in human glioma cells in culture, and possibly to render them more susceptible to chemotherapy and more immunologically responsive. For this purpose we use, singly or in combination, the differentiating agents dimethyl sulfoxide (DMSO), sodium butyrate, retinoic acid, and dexamethasone. These agents are known to affect the synthesis of GAGs in other systems.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
OXIDATIVE METABOLISM IN INHERITED NEUROLOGICAL DISEASES AND MYCOPLASMAS
BIOLOGICAL MODIFICATION OF HUMAN GLIOMA CELLS IN VITRO
STUDIES ON THE MECHANISM OF PATHOGENESIS OF THE MUCOPOLYSACCHARIDOSES
STUDIES ON HUMAN GLIOMA AND RAT PROSTATE ADENOCARCINOMA CELLS IN VITRO
国内基金
海外基金
GMFG/F-actin/cell adhesion 轴驱动 EHT 在造 血干细胞生成中的作用及机制研究
  • 批准号:
    TGY24H080011
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    李鸿鹄
  • 依托单位: